AstraZeneca PLC
Change company Symbol lookup
Select an option...
AZN AstraZeneca PLC
AFAQU AF Acquisition Corp
PTON Peloton Interactive Inc
ETR Entergy Corp
ACMR ACM Research Inc
RGAGX American Funds The Growth Fund of America® Class R-6
ATRC AtriCure Inc
CTRA Coterra Energy Inc
CINF Cincinnati Financial Corp
ATOM Atomera Inc

Health Care : Pharmaceuticals | Large Cap Growth
Based in United Kingdom
Company profile

AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees


Last Trade
-0.29 (-0.44%)
B/A Size

Market Hours

Closing Price
Day's Change
-0.12 (-0.18%)
Bid close
Ask close
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:



6 providers
Today's News, July 01, 2022
AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI(R) (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers

--TOPAZ-1 Phase III trial subgroup analysis showed the addition of IMFINZI to standard-of-care chemotherapy improved overall survival benefit in patients with advanced biliary tract cancer regardless of primary tumor location (BusinessWire)

Yesterday's News, June 30, 2022
IMFINZI(R) (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Response in AEGEAN Phase III Trial in Resectable Non-Small Cell Lung Cancer

Positive high-level results from a planned interim analysis of the AEGEAN Phase III trial showed treatment with AstraZeneca's IMFINZI(R) (durvalumab) in combination with neoadjuvant chemotherapy before surgery demonstrated a statistically...(BusinessWire)

June 23, 2022
ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community

--In Wilson disease, excess copper build-up in organs and tissues can lead to liver disease as well as neurological and psychiatric symptoms Detailed results from the positive FoCus Phase III trial in Wilson disease showed that ALXN1840, an...(BusinessWire)

June 21, 2022
PROpel Phase III Trial Positive Results of LYNPARZA(R) (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence

Results from the PROpel Phase III trial showed that LYNPARZA(R) (olaparib), jointly developed and commercialized by AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, in combination with abiraterone significantly improved...(BusinessWire)

Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis' eplontersen met its co-primary endpoints in a planned interim...(BusinessWire)

June 07, 2022
Breakthroughs In Treating Killer Diseases Could Lengthen Life News Commentary According to the World Health Organization, top global killers include heart failure, COPD, cancers, Alzheimer's, neonatal conditions, and diabetes. Therefore, discovering viable treatments for these issues is...(PR Newswire)

June 05, 2022
ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease

--ENHERTU met the primary endpoint of progression-free survival in patients with HR-positive disease, reducing the risk of disease progression or death by 49% vs. chemotherapy --ENHERTU is the first HER2-directed therapy to demonstrate a survival...(BusinessWire)

June 04, 2022
CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial

Updated results from the ELEVATE-TN Phase III trial showed AstraZeneca's CALQUENCE(R) (acalabrutinib) maintained a statistically significant progression-free survival (PFS) benefit versus chlorambucil plus obinutuzumab and a safety and tolerability...(BusinessWire)

May 27, 2022
First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis

The first patients have been dosed in the IRIS Phase III clinical trial of anifrolumab in lupus nephritis (LN). Up to 60% of patients with lupus develop kidney involvement. In more severe cases, this can develop into LN.(1) LN is characterized by...(BusinessWire)

May 23, 2022
AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022

--Results from multiple trials further reinforce strength of industry-leading portfolio and pipeline, including novel combinations, across cancers with high unmet need AstraZeneca advances its ambition to redefine cancer care with new data to be...(BusinessWire)

May 15, 2022
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma

--MANDALA Phase III trial results published in the New England Journal of Medicine and presented at ATS 2022 International Conference Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different...(BusinessWire)

May 12, 2022
Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing


AstraZeneca Joins Accumulus Synergy as a Sponsor to Accelerate the Delivery of Medicines to Patients

EQNX::TICKER_START (NASDAQ:AZN),(Nasdaq First North Sweden:AZN.ST),(LSE:AZN.L), EQNX::TICKER_END Accumulus Synergy, a nonprofit organization working to develop an information and data exchange platform aimed at transforming how drug innovators and...(Globe Newswire)

May 05, 2022
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022

EQNX::TICKER_START (HKSE:2518),(NYSE:ATHM),(NasdaqGM:LIZI),(NasdaqGM:QH),(NYSE:KUKE),(Other OTC:CLCGY),(Boerse Berlin - Freiverkehr:BOSS),(Other OTC:BOSSY),(HKSE:0142),(NYSE:FPAFY),(LSE:TPK),(Other...(Globe Newswire)

FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction

High-level results from the DELIVER Phase III trial showed AstraZeneca's FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening...(BusinessWire)

ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

--Based on ground-breaking DESTINY-Breast03 results showing ENHERTU reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) AstraZeneca and Daiichi Sankyo's ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) has been...(BusinessWire)

ULTOMIRIS(R) (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder

Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that ULTOMIRIS(R) (ravulizumab-cwvz) achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with...(BusinessWire)

May 04, 2022
Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial

AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally advanced or metastatic...(BusinessWire)

April 28, 2022
ULTOMIRIS(R) (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis

--ULTOMIRIS showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks ULTOMIRIS(R) (ravulizumab-cwvz) has been approved in the US for the treatment of adult...(BusinessWire)

April 27, 2022
ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer

--ENHERTU has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers AstraZeneca and Daiichi Sankyo's ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) has been granted...(BusinessWire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.